Clinical beta

FMBM is currently in clinical beta. Content is for professional review/testing and must not replace local protocols, senior clinical judgment, or official prescribing references.

Drug Monograph

Ceftazidime

Ceftazidime

Third-generation anti-pseudomonal cephalosporin (IV)

PseudomonasGNRIVΞ²-lactam

Indication

HAP/VAP (susceptible) β€’ febrile neutropenia (combo) β€’ pyelonephritis (GNR) β€’ meningitis (combo, susceptible)

At a glance

INDICATIONS (CORE USE)

Pseudomonas + many gram-negatives β€” **weak gram-positive** (not MSSA drug of choice).

ADULT DOSE (STANDARD)

1–2 g IV q8h; extended/continuous infusion in some protocols; severe 2 g q8h

MAX DOSE

~9 g/day adult in extended-infusion protocols (institution-specific)

Route

IV, IM

PEDIATRIC DOSE

Weight-based q8h per peds reference

Do not miss

Must-not-miss safety points

Major warning

- Ξ²-lactam anaphylaxis - **Poor strep/MSSA reliability** β€” do not substitute for anti-staph beta-lactam when staph is concern - Renal dose adjustment - ESBL / carbapenem-resistant organisms β€” treatment failure if mis-selected

Indications

USE IF: Pseudomonas or susceptible GNR infection where ceftazidime fits antibiogram. AVOID IF: MSSA/MRSA serious infection as sole beta-lactam; enterococcal endocarditis; ESBL without carbapenem plan.

Primary

  • Pseudomonas aeruginosa infection (susceptible) including pneumonia / bacteremia with source control
  • Complicated UTI/pyelonephritis due to susceptible resistant GNR (institution-dependent)

Secondary

  • Febrile neutropenia as part of combination regimen per ID guideline
  • Meningitis in combination when pathogen susceptible (rare niche)

Other

  • Synergy with aminoglycoside for pseudomonal bacteremia (nephrotoxicity trade-off)

Dosing

STANDARD (ADULT PO)

1–2 g IV q8h (2 g common for serious Pseudomonas)

ADULT DOSE

2 g IV q8h common for serious pseudomonal infection; 1 g q8h moderate; consider extended infusion for PK/PD

PEDIATRIC DOSE

Per pediatric pseudomonas dosing tables.

MAX DOSE

High-dose extended infusion protocols exist β€” pharmacy-driven.

Practical Note

Combine with second agent for high-risk pseudomonal bacteremia per local guideline.

Warnings

Clinical warnings

  • **Ξ²-lactam allergy β€” immediate** (anaphylaxis, angioedema, bronchospasm, hypotension) β†’ **avoid** this agent; use non–β-lactam alternative
  • **Ξ²-lactam allergy β€” non-severe** (maculopapular rash without systemic anaphylaxis features) β†’ **caution**; risk/benefit + allergy/ID pathway; graded challenge or test dose **only** per protocol β€” do not dismiss automatically
  • **Neurotoxicity:** encephalopathy, confusion, myoclonus, seizures β€” **higher risk with CKD, elderly, dose accumulation** (notably cefepime, carbapenems, high-dose penicillins)
  • New CNS symptoms + renal impairment on IV Ξ²-lactam β†’ **hold dose**, check levels/exposure, rule out other causes
  • Neurotoxicity with accumulation
  • C. diff

Adverse effects

  • rash
  • phlebitis
  • drug fever

Contraindications

  • Cephalosporin anaphylaxis when alternative mandated

Drug interactions

  • Aminoglycosides β€” additive nephrotoxicity
  • Probenecid

Special populations

Pediatrics

Weight-based q8h per peds reference

Pregnancy

Use when benefit > risk

Lactation

generally low risk.

Renal impairment

Mandatory adjustment in CKD; HD supplemental dosing. **CrCl scaffold (FMBM β€” titrate to FDA/SFDA label + institutional pharmacy nomogram):** - **CrCl β‰₯50** β†’ standard interval (per Adult dosing card) - **CrCl 10–50** β†’ extend interval and/or reduce dose (often q12–24h or ↓ dose β€” **product-specific**) - **CrCl <10** β†’ maximal interval extension / dose reduction; **HD: redose post-dialysis** per protocol; AKI β†’ re-estimate CrCl; **neuro signs** β†’ hold/adjust

Hepatic impairment

No standard monotherapy adjustment.

Elderly

Renal dosing paramount.

Administration

IV infusion; stability per diluent.

Monitoring

  • Monitor: - ICU or CKD β†’ **creatinine daily** β†’ underdosing in AKI vs accumulation / **neurotoxicity** if not adjusted - New confusion / myoclonus / seizures + renal impairment on IV Ξ²-lactam β†’ **hold dose** β†’ evaluate encephalopathy - Serious GNR infection β†’ extended-infusion / pharmacy optimization per protocol - Renal function on aminoglycoside combo
  • Recheck: - Clinical/radiographic response in pneumonia 48–72h - No clinical improvement at 48–72h β†’ reassess diagnosis, resistance, source control, and drug interactions - If targets not met after reassessment of dose, organ function, and interactions β†’ escalate per protocol (DO NOT continue blindly)

Overdose / toxicity

Clinical Picture

**Life-threatening (first):** **CNS toxicity** β€” seizures, encephalopathy, agitation, myoclonus, coma (**↑ CKD, elderly, accumulation**; cefepime, carbapenems, high-dose penicillins). **Allergic:** anaphylaxis / angioedema (separate pathway). **Secondary:** nausea/vomiting/diarrhea mainly with acute massive **oral** co-ingestion or local infusion reaction.

Immediate Actions

Stop Ξ²-lactam β†’ ABCs β†’ **seizure precautions**; benzos if seizures; check renal function / dose vs CrCl; anaphylaxis β†’ epinephrine + ACLS

Antidote

No specific antidote; treat complications (e.g. anaphylaxis β†’ epinephrine per ACLS)

Decontamination

Stop infusion; recent large PO load β†’ charcoal if protected airway + early presentation

Escalation

Status epilepticus, coma, refractory seizures β†’ **ICU**; **severe CNS toxicity or AKI with accumulation β†’ consider hemodialysis** for dialyzable agents β€” nephrology + pharmacy; persistent anaphylaxis β†’ ICU

Clinical pearls

Common mistakes, resistance logic, and bedside traps

High-Yield Summary

Anti-pseudomonal Ξ²-lactam β€” **not** your MSSA monotherapy. Renal adjust. Think **dual therapy** for high-risk pseudomonal bacteremia.

Clinical pearls

Stewardship: de-escalate from double gram-negative coverage when cultures negative. Resistance: document MIC trends for Pseudomonas. *Stewardship (all antimicrobials):* Empiric choice β†’ syndrome severity + **local antibiogram**; shortest effective course.

Stewardship & safety

  • GP coverage gap
  • Renal dose
  • Combo therapy rules

Pharmacokinetics

Renal elimination; CSF penetration with inflamed meninges at high dose.

Mechanism of action

Anti-pseudomonal third-gen cephalosporin β€” PBP affinity skewed to gram-negatives.

Common brand names

Saudi Arabia

Fortum, Tazidime

Global

Fortaz, (placeholder β€” verify local formulary)

Common trade names are curated examples only β€” formulations and availability vary. Verify the exact product name with your local pharmacy and national regulator before prescribing or dispensing.

Country practice notes

  • Empiric choice β†’ tie to syndrome, severity, and local antibiogram β€” not habit.
  • IV β†’ PO step-down when oral bioavailability and susceptibility allow.
  • Do not use antibiotics for uncomplicated viral illness β€” stewardship.

References

Saudi Arabia

  • SFDA (Saudi Food & Drug Authority)
  • Saudi National Formulary / MOH (where available)

International

  • WHO Model List of Essential Medicines (verify current edition)
  • US FDA or EU EMA product information (when national SmPC is unavailable)
  • Sanford Guide
  • IDSA / ESCMID (indication-specific)
  • Local antimicrobial stewardship / hospital formulary
  • FDA / SFDA / regional product labeling
  • Sanford Guide
  • IDSA / ESCMID (indication-specific)
  • Local antimicrobial stewardship / hospital formulary
  • FDA / SFDA / regional product labeling

Do not miss

  • Uncomplicated viral URI/bronchitis β†’ antibiotics rarely indicated
  • Narrow or stop when susceptibilities + clinical stability allow
  • Staph coverage gap.
  • ESBL mismatch.
  • Neurotoxicity if dosed in anuric patient without adjustment.
  • GP coverage gap
  • Renal dose
  • Combo therapy rules